Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

Click to increase image sizeClick to decrease image size

Authors contributions

C.D.G. designed the study, performed research, interpreted data and wrote the manuscript. O.M.B., S.R.J., G.S.L., E.E.G., M.E.B., and M.H.C. performed research, interpreted data and revised the manuscript. R.B.W. designed and supervised the study, interpreted data and wrote the manuscript.

Disclosure statement

S.R.J. and M.H.C. are employees of Eutropics Pharmaceuticals, Inc. R.B.W. received laboratory research grants and/or clinical trial support from Actinium Pharmaceuticals, Agios, Amgen, Aptevo Therapeutics, Arog, BioLineRx, Jazz, Pfizer, Seattle Genetics, and Selvita; has ownership interests with Amphivena Therapeutics; and is (or has been) a consultant to Agios, Amphivena Therapeutics, Astellas, BiVictrix, Boehringer Ingelheim, Covagen, Emergent Biosolutions/Aptevo Therapeutics, Jazz, Kite, Pfizer, and Seattle Genetics. The other authors declare no competing financial interests.

Additional information

Funding

Research reported in this publication was supported by the Leukemia & Lymphoma Society (Translational Research Program, grant 6489-16) and the National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant (P30-CA015704). C.D.G. is supported by a fellowship training grant from the National Heart, Lung, and Blood Institute (NHLBI)/NIH (T32-HL007093) and an institutional K12 grant from the National Cancer Institute (K12-CA076930). S.R.J. and M.H.C. receive support from the NIH/NCI Small Business Innovation Research (SBIR) grant R44-CA203610.